Dr. Damian Silvia

Graduated in Medicine and Surgery from the University of Bologna in 2005, she obtained a specialization in Medical Oncology in 2009 from the University of Milan. Since 2009, she has been engaged in clinical and research activities at the Medical Oncology Unit 1.

Over the years, she has specialized in the development of new drugs and personalized medicine for the treatment of solid tumors. She has gained extensive experience in the evaluation and clinical management of oncology patients enrolled in early-phase clinical trials, covering a wide range of advanced solid tumors, with particular expertise in breast cancer therapy.

As a Principal Investigator or co-investigator, she has conducted more than 90 Phase 1 and 2 protocols, including first-in-human trials, assessing the toxicity profile and activity of numerous innovative drugs, such as targeted molecular therapies, antibody-drug conjugates, and next-generation immunotherapies.

She is a member of the Qualified Personnel Organizational Chart for conducting Phase 1 studies at the Foundation, in compliance with AIFA Determination 809/2015. She is also a permanent member of the institutional Molecular Tumor Board (MTB), dedicated to the weekly discussion of molecular data and potential therapeutic options for patients with advanced solid tumors.

In recent years, she has actively participated in projects within the field of Digital Health, contributing to the development of various digital tools aimed at clinical research and patient communication, such as PROACT 2.0 ( https://upsmart.digitalecmt.com/proact/ ).

She is a member of the scientific societies ESMO and AIOM